This statistic was assembled from several editions of Novartis' annual report. * With the 2015 Annual Report, values back to 2011 were restated, as a result of a series of transactions during 2015. ** During this year, eye care division Alcon was spun off and became an own company. Thus...
人狂犬病疫苗(Novartis ): 一种免疫刺激剂药物,由Novartis Vaccines & Diagnostics, Inc. (Novartis Vaccines & Diagnostics, Inc.)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: 免疫刺激剂,治疗领域: 感染,其他疾病,在研适应症: 狂犬病,在研机构: Chi
You should specifically consider the factors identified in this document, in addition to the risk factors that may affect GSK’s operations which are described under “Risk Factors” in the Company’s 2013 Ann...
sectors and the economy. ICICI Securities Report JB Chemicals and Pharmaceuticals Ltd. is licensing ophthalmic brands from Novartis, marking its foray in this therapy. It will make a cumulative payment of Rs 10.89 billion for in-licensing the 10 brands of Novartis for three years, post which it...
Moreira Da Silva, “Nivolumab Anti-PD-1 monoclonal antibody cancer immunotherapy” Drugs of the Future (2014) vol. 39 No. 1 pp. 15-24. Naing et al. “A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors” 2016 ASCO Annual Meeting,...
摘要: Swiss pharmaceutical giant Novartis AG says fourth quarter net income dropped 26 percent but the company still posted a healthy 2014 annual profit.DOI: urn:uuid:775ce0d380a2b410VgnVCM100000d7c1a8c0RCRD 年份: 2015 收藏 引用 批量引用 报错 分享 ...
We use a number of adjusted, non-IFRS, measures to report the performance of our business, as described on page 58 of GSK’s 2017 Annual Report, including Adjusted results, free cash flow and CER growth rates. Non-IFRS measures may be considered in addition ...